CZECRIN NETWORKS

Disease-oriented Networks’ expertise validates new scientific ideas and hypotheses generated by clinical experts in clinical trials, thus improving patient treatment outcomes. These specialized networks focused on a specific diagnosis or field connecting experts and workplaces throughout the Czech Republic and enable the effective, successful implementation of non-commercial clinical trials, including nationwide and international projects. The networks associated in DONet share the CZECRIN support and professional capacities and cooperates closely with other networks. The cooperation of the networks associated in DONet and the CTU / CTC or ECRIN-ERIC networks creates a powerful instrument enabling a close connection between clinical experts postulating scientific hypotheses and their subsequent clinical evaluation  in/through clinical studies on a national and/or international scale. Priority fields with a dedicated network currently include personalized clinical trials in oncology, pediatric indications, rare diseases, stroke, infectious diseases, and clinical trials with advanced therapy medicinal products (ATMP). CZECRIN plans to enhance cooperation within diseases such as cardiology, pneumology, hemato-oncology, perinatology, psychiatry and psychopharmacology or epileptology in upcoming years.

Phase 1 clinical trial is the first phase in which a newly developed drug is administered to a human (first-in-humans). Phase 1 trials are designed to test the safety, side effects, maximum-tolerated dose and drug pharmacokinetic parameters. The primary goal of phase I is not yet to verify efficacy. The aim is to prove that the drug being developed cannot cause serious harm to anyone. Phase I trials most often include healthy volunteers and is a crucial phase for further clinical research. The evaluation takes place under strictly controlled conditions and in specialized phase 1 units with full medical support. These units enable early phase clinical trials in full compliance with all legislative requirements, compliance with Good Clinical Practice (ICH GCP) and international standards.